Molina et al. Dupilumab (IL4/IL13 mab) in refractory EGPA. Complete response 49%, partial 43%. But flares in 27%. Dupilumab-induced eosinophilia in 57%. @RheumNow #ACR22 Abstr#1074 https://t.co/cziyHNPN3j https://t.co/h7gWAShQeL
Links:
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory E…
https://acrabstracts.org/abstract/safety-and-efficacy-of-dupilumab-in-patients-…
13-11-2022
